JP2012506848A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506848A5
JP2012506848A5 JP2011532652A JP2011532652A JP2012506848A5 JP 2012506848 A5 JP2012506848 A5 JP 2012506848A5 JP 2011532652 A JP2011532652 A JP 2011532652A JP 2011532652 A JP2011532652 A JP 2011532652A JP 2012506848 A5 JP2012506848 A5 JP 2012506848A5
Authority
JP
Japan
Prior art keywords
methyl
carboxamide
dihydro
pyrazole
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011532652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506848A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064015 external-priority patent/WO2010049366A1/en
Publication of JP2012506848A publication Critical patent/JP2012506848A/ja
Publication of JP2012506848A5 publication Critical patent/JP2012506848A5/ja
Withdrawn legal-status Critical Current

Links

JP2011532652A 2008-10-27 2009-10-23 グルタミン酸受容体モジュレーターとしての三環式化合物 Withdrawn JP2012506848A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10866608P 2008-10-27 2008-10-27
US61/108,666 2008-10-27
PCT/EP2009/064015 WO2010049366A1 (en) 2008-10-27 2009-10-23 Tricyclic compounds as glutamate receptor modulators

Publications (2)

Publication Number Publication Date
JP2012506848A JP2012506848A (ja) 2012-03-22
JP2012506848A5 true JP2012506848A5 (enExample) 2012-11-29

Family

ID=41401883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532652A Withdrawn JP2012506848A (ja) 2008-10-27 2009-10-23 グルタミン酸受容体モジュレーターとしての三環式化合物

Country Status (4)

Country Link
US (1) US20110263588A1 (enExample)
EP (1) EP2346832A1 (enExample)
JP (1) JP2012506848A (enExample)
WO (1) WO2010049366A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151361A1 (en) * 2010-06-03 2011-12-08 Glaxo Group Limited Novel compounds
RU2663898C2 (ru) 2013-06-24 2018-08-13 Мерк Патент Гмбх Пиразольные соединения в качестве модуляторов fshr и их применение
EP3288948B1 (en) * 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
DK3341376T3 (da) 2015-08-26 2021-03-29 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
BR112018074231A2 (pt) * 2016-05-25 2019-03-06 Akarna Therapeutics, Ltd. compostos bicíclicos fundidos para o tratamento de doença
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
US12441727B2 (en) 2021-07-07 2025-10-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Krasの阻害剤としてのナフチリジン化合物
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンkras阻害剤
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof
CN120682241A (zh) * 2024-03-22 2025-09-23 复旦大学附属中山医院 三环骨架化合物及其在制备抗肿瘤药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318691D0 (en) * 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
EP1427706B1 (en) * 2001-09-19 2007-05-30 Pharmacia Corporation Substituted pyrazolo compounds for the treatment of inflammation
US20060281803A1 (en) * 2003-09-23 2006-12-14 Lindsley Craig W Pyrazole modulators of metabotropic glutamate receptors
WO2008035356A2 (en) * 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands

Similar Documents

Publication Publication Date Title
JP2012506848A5 (enExample)
Heravi et al. Prescribed drugs containing nitrogen heterocycles: an overview
RU2018123779A (ru) Новые соединения
ES2620612T3 (es) Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
HRP20180413T1 (hr) Inhibitori kinaza koji reguliraju signalne puteve u apoptozi
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2010513444A5 (enExample)
CN106132956A (zh) 一类杂环化合物、其制备方法和用途
ES2734735T3 (es) Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139
JP2006520805A5 (enExample)
JP2011510995A5 (enExample)
JP2008507539A5 (enExample)
JP2020526556A5 (enExample)
JP2012532931A5 (enExample)
JP2009529047A5 (enExample)
WO2008034008A2 (en) Kinase inhibitors useful for the treatment of proliferative diseases
JP2006502112A5 (enExample)
JP2007510689A5 (enExample)
WO2009037001A4 (en) Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
CA2504385A1 (en) Thiadiazine compounds and uses thereof
KR20130142153A (ko) 복소환 아민 및 이의 용도
IL171480A (en) Aza spiro alkane derivatives as inhibitors of metalloproteases and pharmaceutical compositions and uses thereof
JP2018525375A5 (enExample)
JP2019536768A5 (enExample)
AU2005215257A1 (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists